This page has only limited features, please log in for full access.

Unclaimed
Agnieszka Cieślicka-Kapłon
Department of Cardiology, Medical University of Warsaw, 02-097 Warsaw, Poland

Basic Info

Basic Info is private.

Honors and Awards

The user has no records in this section


Career Timeline

The user has no records in this section.


Short Biography

Doctor Kapłon-Cieślicka is a cardiologist, a certified echocardiographer and an assistant professor at the 1 st Chair and Department of Cardiology, Medical University of Warsaw. She defended her PhD cum laude in 2012, and obtained her post-doctoral degree in 2017. Her current clinical and research interests revolve around heart failure (including heart failure with preserved ejection fraction), atrial fibrillation and valvular disease. She is a co- author of over 80 publications indexed in PubMed with an IF of over 160 and a h-index of 16. She is also the President of the “Club 30” of the Polish Cardiac Society.

Following
Followers
Co Authors
The list of users this user is following is empty.
Following: 0 users

Feed

Journal article
Published: 28 May 2021 in Journal of Clinical Medicine
Reads 0
Downloads 0

MicroRNAs are endogenous non-coding RNAs that are involved in numerous biological processes through regulation of gene expression. The aim of our study was to determine the ability of several miRNAs to predict mortality and response to antiplatelet treatment among T2DM patients. Two hundred fifty-two patients with diabetes were enrolled in the study. Among the patients included, 26 (10.3%) patients died within a median observation time of 5.9 years. The patients were receiving either acetylsalicylic acid (ASA) 75 mg (65%), ASA 150 mg (15%) or clopidogrel (19%). Plasma miR-126, miR-223, miR-125a-3p and Let-7e expressions were assessed by quantitative real time PCR and compared between the patients who survived and those who died. Adjusted Cox-regression analysis was used for prediction of mortality. Differential miRNA expression due to different antiplatelet treatment was analyzed. After including all miRNAs into one multivariate Cox regression model, only miR-126 was predictive of future occurrence of long-term all-cause death (HR = 5.82, 95% CI: 1.3–24.9; p = 0.024). Furthermore, miR-126, Let-7e and miR-223 expressions in the clopidogrel group were significantly higher than in the ASA group (p = 0.014; p = 0.013; p = 0.028, respectively). To conclude, miR-126 expression is a strong and independent predictor of long-term all-cause mortality among patients with T2DM. Moreover, miR-223, miR-126 and Let-7e present significant interactions with antiplatelet treatment regimens and clinical outcomes.

ACS Style

Justyna Pordzik; Ceren Eyileten-Postuła; Daniel Jakubik; Pamela Czajka; Anna Nowak; Salvatore De Rosa; Aleksandra Gąsecka; Agnieszka Cieślicka-Kapłon; Piotr Sulikowski; Krzysztof Filipiak; Dagmara Mirowska-Guzel; Jolanta Siller-Matula; Marek Postuła. MiR-126 Is an Independent Predictor of Long-Term All-Cause Mortality in Patients with Type 2 Diabetes Mellitus. Journal of Clinical Medicine 2021, 10, 2371 .

AMA Style

Justyna Pordzik, Ceren Eyileten-Postuła, Daniel Jakubik, Pamela Czajka, Anna Nowak, Salvatore De Rosa, Aleksandra Gąsecka, Agnieszka Cieślicka-Kapłon, Piotr Sulikowski, Krzysztof Filipiak, Dagmara Mirowska-Guzel, Jolanta Siller-Matula, Marek Postuła. MiR-126 Is an Independent Predictor of Long-Term All-Cause Mortality in Patients with Type 2 Diabetes Mellitus. Journal of Clinical Medicine. 2021; 10 (11):2371.

Chicago/Turabian Style

Justyna Pordzik; Ceren Eyileten-Postuła; Daniel Jakubik; Pamela Czajka; Anna Nowak; Salvatore De Rosa; Aleksandra Gąsecka; Agnieszka Cieślicka-Kapłon; Piotr Sulikowski; Krzysztof Filipiak; Dagmara Mirowska-Guzel; Jolanta Siller-Matula; Marek Postuła. 2021. "MiR-126 Is an Independent Predictor of Long-Term All-Cause Mortality in Patients with Type 2 Diabetes Mellitus." Journal of Clinical Medicine 10, no. 11: 2371.

Journal article
Published: 22 April 2021 in Journal of Clinical Medicine
Reads 0
Downloads 0

Background: Hyperuricemia is an established risk factor for cardiovascular disease, including atrial fibrillation (AF). The prevalence of hyperuricemia and its clinical significance in patients with already diagnosed AF remain unexplored. Methods: The Polish Atrial Fibrillation (POL-AF) registry includes consecutive patients with AF hospitalized in 10 Polish cardiology centers from January to December 2019. This analysis included patients in whom serum uric acid (SUA) was measured. Results: From 3999 POL-AF patients, 1613 were included in the analysis. The mean age of the subjects was 72 ± 11.6 years, and the mean SUA was 6.88 ± 1.93 mg/dL. Hyperuricemia was found in 43% of respondents. Eighty-four percent of the respondents were assigned to the high cardiovascular risk group, and 45% of these had SUA >7 mg/dL. Comparison of the extreme SUA groups (7 mg/dL) showed significant differences in renal parameters, total cholesterol concentration, and left ventricular ejection fraction (EF). Multivariate regression analysis showed that SUA >7 mg/dL (OR 1.74, 95% CI 1.32–2.30) and GFR <60 mL/min/1.73 m2 (OR 1.94, 95% CI 1.46–2.48) are significant markers of EF <40% in the study population. Female sex was a protective factor (OR 0.74, 95% CI 0.56–0.97). The cut-off point for SUA with 60% sensitivity and specificity indicative of an EF <40% was 6.9 mg/dL. Conclusions: Although rarely assessed, hyperuricemia appears to be common in patients with AF. High SUA levels may be a significant biomarker of reduced left ventricular EF in AF patients.

ACS Style

Marcin Wełnicki; Iwona Gorczyca; Wiktor Wójcik; Olga Jelonek; Małgorzata Maciorowska; Beata Uziębło-Życzkowska; Maciej Wójcik; Robert Błaszczyk; Renata Rajtar-Salwa; Tomasz Tokarek; Jacek Bil; Michał Wojewódzki; Anna Szpotowicz; Małgorzata Krzciuk; Monika Gawałko; Agnieszka Kapłon-Cieślicka; Anna Tomaszuk-Kazberuk; Anna Szyszkowska; Janusz Bednarski; Elwira Bakuła-Ostalska; Beata Wożakowska-Kapłon; Artur Mamcarz. Hyperuricemia as a Marker of Reduced Left Ventricular Ejection Fraction in Patients with Atrial Fibrillation: Results of the POL-AF Registry Study. Journal of Clinical Medicine 2021, 10, 1829 .

AMA Style

Marcin Wełnicki, Iwona Gorczyca, Wiktor Wójcik, Olga Jelonek, Małgorzata Maciorowska, Beata Uziębło-Życzkowska, Maciej Wójcik, Robert Błaszczyk, Renata Rajtar-Salwa, Tomasz Tokarek, Jacek Bil, Michał Wojewódzki, Anna Szpotowicz, Małgorzata Krzciuk, Monika Gawałko, Agnieszka Kapłon-Cieślicka, Anna Tomaszuk-Kazberuk, Anna Szyszkowska, Janusz Bednarski, Elwira Bakuła-Ostalska, Beata Wożakowska-Kapłon, Artur Mamcarz. Hyperuricemia as a Marker of Reduced Left Ventricular Ejection Fraction in Patients with Atrial Fibrillation: Results of the POL-AF Registry Study. Journal of Clinical Medicine. 2021; 10 (9):1829.

Chicago/Turabian Style

Marcin Wełnicki; Iwona Gorczyca; Wiktor Wójcik; Olga Jelonek; Małgorzata Maciorowska; Beata Uziębło-Życzkowska; Maciej Wójcik; Robert Błaszczyk; Renata Rajtar-Salwa; Tomasz Tokarek; Jacek Bil; Michał Wojewódzki; Anna Szpotowicz; Małgorzata Krzciuk; Monika Gawałko; Agnieszka Kapłon-Cieślicka; Anna Tomaszuk-Kazberuk; Anna Szyszkowska; Janusz Bednarski; Elwira Bakuła-Ostalska; Beata Wożakowska-Kapłon; Artur Mamcarz. 2021. "Hyperuricemia as a Marker of Reduced Left Ventricular Ejection Fraction in Patients with Atrial Fibrillation: Results of the POL-AF Registry Study." Journal of Clinical Medicine 10, no. 9: 1829.

Journal article
Published: 24 March 2021 in Journal of Clinical Medicine
Reads 0
Downloads 0

Background: We aimed to assess characteristics and treatment of AF patients with and without heart failure (HF). Methods: The prospective, observational Polish Atrial Fibrillation (POL-AF) Registry included consecutive patients with AF hospitalized in 10 Polish cardiology centers in 2019–2020. Results: Among 3999 AF patients, 2822 (71%) had HF (AF/HF group). Half of AF/HF patients had preserved ejection fraction (HFpEF). Compared to patients without HF (AF/non–HF), AF/HF patients were older, more often male, more often had permanent AF, and had more comorbidities. Of AF/HF patients, 98% had class I indications to oral anticoagulation (OAC). Still, 16% of patients were not treated with OAC at hospital admission, and 9%—at discharge (regardless of the presence of HF and its subtypes). Of patients not receiving OAC upon admission, 61% were prescribed OAC (most often apixaban) at discharge. AF/non–HF patients more often converted from AF at admission to sinus rhythm at discharge compared to AF/HF patients (55% vs. 30%), despite cardioversion performed as often in both groups. Class I antiarrhythmics were more often prescribed in AF/non–HF than in AF/HF group (13% vs. 8%), but still as many as 15% of HFpEF patients received them. Conclusions: Over 70% of hospitalized AF patients have coexisting HF. A significant number of AF patients does not receive the recommended OAC.

ACS Style

Monika Gawałko; Monika Budnik; Iwona Gorczyca; Olga Jelonek; Beata Uziębło-Życzkowska; Małgorzata Maciorowska; Maciej Wójcik; Robert Błaszczyk; Tomasz Tokarek; Renata Rajtar-Salwa; Jacek Bil; Michał Wojewódzki; Anna Szpotowicz; Małgorzata Krzciuk; Janusz Bednarski; Elwira Bakuła-Ostalska; Anna Tomaszuk-Kazberuk; Anna Szyszkowska; Marcin Wełnicki; Artur Mamcarz; Agnieszka Kapłon-Cieślicka. Characteristics and Treatment of Atrial Fibrillation with Respect to the Presence or Absence of Heart Failure. Insights from the Multicenter Polish Atrial Fibrillation (POL-AF) Registry. Journal of Clinical Medicine 2021, 10, 1341 .

AMA Style

Monika Gawałko, Monika Budnik, Iwona Gorczyca, Olga Jelonek, Beata Uziębło-Życzkowska, Małgorzata Maciorowska, Maciej Wójcik, Robert Błaszczyk, Tomasz Tokarek, Renata Rajtar-Salwa, Jacek Bil, Michał Wojewódzki, Anna Szpotowicz, Małgorzata Krzciuk, Janusz Bednarski, Elwira Bakuła-Ostalska, Anna Tomaszuk-Kazberuk, Anna Szyszkowska, Marcin Wełnicki, Artur Mamcarz, Agnieszka Kapłon-Cieślicka. Characteristics and Treatment of Atrial Fibrillation with Respect to the Presence or Absence of Heart Failure. Insights from the Multicenter Polish Atrial Fibrillation (POL-AF) Registry. Journal of Clinical Medicine. 2021; 10 (7):1341.

Chicago/Turabian Style

Monika Gawałko; Monika Budnik; Iwona Gorczyca; Olga Jelonek; Beata Uziębło-Życzkowska; Małgorzata Maciorowska; Maciej Wójcik; Robert Błaszczyk; Tomasz Tokarek; Renata Rajtar-Salwa; Jacek Bil; Michał Wojewódzki; Anna Szpotowicz; Małgorzata Krzciuk; Janusz Bednarski; Elwira Bakuła-Ostalska; Anna Tomaszuk-Kazberuk; Anna Szyszkowska; Marcin Wełnicki; Artur Mamcarz; Agnieszka Kapłon-Cieślicka. 2021. "Characteristics and Treatment of Atrial Fibrillation with Respect to the Presence or Absence of Heart Failure. Insights from the Multicenter Polish Atrial Fibrillation (POL-AF) Registry." Journal of Clinical Medicine 10, no. 7: 1341.

Journal article
Published: 05 March 2021 in Journal of Clinical Medicine
Reads 0
Downloads 0

Background: Atrial fibrillation (AF) can cause severe symptoms, but it is frequently asymptomatic. We aimed to compare the clinical features of patients with asymptomatic and symptomatic AF. Methods: A prospective, observational, multicenter study was performed (the Polish Atrial Fibrillation (POL-AF) registry). Consecutive hospitalized AF patients over 18 years of age were enrolled at ten centers. The data were collected for two weeks during each month of 2019. Results: A total of 2785 patients were analyzed, of whom 1360 were asymptomatic (48.8%). Asymptomatic patients were more frequently observed to have coronary artery disease (57.5% vs. 49.1%, p < 0.0001), heart failure with preserved ejection fraction (39.8% vs. 26.5%, p < 0.0001), a previous thromboembolic event (18.2% vs. 13.1%, p = 0.0002), and paroxysmal AF (52.3% vs. 45.2%, p = 0.0002). In multivariate analysis, history of electrical cardioversion, paroxysmal AF, heart failure, coronary artery disease, previous thromboembolic event, and higher left ventricular ejection fraction were predictors of a lack of AF symptoms. First-diagnosed AF was a predictor of AF symptoms. Conclusions: In comparison to symptomatic patients, more of those hospitalized with asymptomatic AF had been previously diagnosed with this arrhythmia and other cardiovascular diseases. However, they presented with better left ventricular function and were more frequently treated with cardiovascular medicines.

ACS Style

Marek Kiliszek; Beata Uziębło-Życzkowska; Iwona Gorczyca; Małgorzata Maciorowska; Olga Jelonek; Beata Wożakowska-Kapłon; Maciej Wójcik; Robert Błaszczyk; Monika Gawałko; Agnieszka Kapłon-Cieślicka; Tomasz Tokarek; Renata Rajtar-Salwa; Jacek Bil; Michał Wojewódzki; Anna Szpotowicz; Małgorzata Krzciuk; Janusz Bednarski; Elwira Bakuła-Ostalska; Anna Tomaszuk-Kazberuk; Anna Szyszkowska; Marcin Wełnicki; Artur Mamcarz; Paweł Krzesiński. Symptomatic and Asymptomatic Patients in the Polish Atrial Fibrillation (POL-AF) Registry. Journal of Clinical Medicine 2021, 10, 1091 .

AMA Style

Marek Kiliszek, Beata Uziębło-Życzkowska, Iwona Gorczyca, Małgorzata Maciorowska, Olga Jelonek, Beata Wożakowska-Kapłon, Maciej Wójcik, Robert Błaszczyk, Monika Gawałko, Agnieszka Kapłon-Cieślicka, Tomasz Tokarek, Renata Rajtar-Salwa, Jacek Bil, Michał Wojewódzki, Anna Szpotowicz, Małgorzata Krzciuk, Janusz Bednarski, Elwira Bakuła-Ostalska, Anna Tomaszuk-Kazberuk, Anna Szyszkowska, Marcin Wełnicki, Artur Mamcarz, Paweł Krzesiński. Symptomatic and Asymptomatic Patients in the Polish Atrial Fibrillation (POL-AF) Registry. Journal of Clinical Medicine. 2021; 10 (5):1091.

Chicago/Turabian Style

Marek Kiliszek; Beata Uziębło-Życzkowska; Iwona Gorczyca; Małgorzata Maciorowska; Olga Jelonek; Beata Wożakowska-Kapłon; Maciej Wójcik; Robert Błaszczyk; Monika Gawałko; Agnieszka Kapłon-Cieślicka; Tomasz Tokarek; Renata Rajtar-Salwa; Jacek Bil; Michał Wojewódzki; Anna Szpotowicz; Małgorzata Krzciuk; Janusz Bednarski; Elwira Bakuła-Ostalska; Anna Tomaszuk-Kazberuk; Anna Szyszkowska; Marcin Wełnicki; Artur Mamcarz; Paweł Krzesiński. 2021. "Symptomatic and Asymptomatic Patients in the Polish Atrial Fibrillation (POL-AF) Registry." Journal of Clinical Medicine 10, no. 5: 1091.

Journal article
Published: 30 January 2021 in Biology
Reads 0
Downloads 0

Background, the mechanisms underlying left ventricular remodelling (LVR) after acute myocardial infarction (AMI) remain obscure. In the course of AMI, blood cells and endothelial cells release extracellular vesicles (EVs). We hypothesized that changes in EV concentrations after AMI may underlie LVR. Methods, plasma concentrations of EVs from endothelial cells (CD146+), erythrocytes (CD235a+), leukocytes (CD45+), platelets (CD61+), activated platelets (P-selectin+), and EVs exposing phosphatidylserine after AMI were determined by flow cytometry in 55 patients with the first AMI. LVR was defined as an increase in left ventricular end-diastolic volume by 20% at 6 months after AMI, compared to baseline. Results, baseline concentrations of EVs from endothelial cells, erythrocytes and platelets were lower in patients who developed LVR (p ≤ 0.02 for all). Concentrations of EVs from endothelial cells and erythrocytes were independent LVR predictors (OR 8.2, CI 1.3–54.2 and OR 17.8, CI 2.3–138.6, respectively) in multivariate analysis. Combining the three EV subtypes allowed to predict LVR with 83% sensitivity and 87% specificity. Conclusions, decreased plasma concentrations of EVs from endothelial cells, erythrocytes and platelets predict LVR after AMI. Since EV release EVs contributes to cellular homeostasis by waste removal, decreased concentrations of EVs may indicate dysfunctional cardiac homeostasis after AMI, thus promoting LVR.

ACS Style

Aleksandra Gąsecka; Kinga Pluta; Katarzyna Solarska; Bartłomiej Rydz; Ceren Eyileten; Marek Postula; Edwin van der Pol; Rienk Nieuwland; Monika Budnik; Janusz Kochanowski; Miłosz Jaguszewski; Łukasz Szarpak; Tomasz Mazurek; Agnieszka Kapłon-Cieślicka; Grzegorz Opolski; Krzysztof Filipiak. Plasma Concentrations of Extracellular Vesicles are Decreased in Patients with Post-Infarct Cardiac Remodelling. Biology 2021, 10, 97 .

AMA Style

Aleksandra Gąsecka, Kinga Pluta, Katarzyna Solarska, Bartłomiej Rydz, Ceren Eyileten, Marek Postula, Edwin van der Pol, Rienk Nieuwland, Monika Budnik, Janusz Kochanowski, Miłosz Jaguszewski, Łukasz Szarpak, Tomasz Mazurek, Agnieszka Kapłon-Cieślicka, Grzegorz Opolski, Krzysztof Filipiak. Plasma Concentrations of Extracellular Vesicles are Decreased in Patients with Post-Infarct Cardiac Remodelling. Biology. 2021; 10 (2):97.

Chicago/Turabian Style

Aleksandra Gąsecka; Kinga Pluta; Katarzyna Solarska; Bartłomiej Rydz; Ceren Eyileten; Marek Postula; Edwin van der Pol; Rienk Nieuwland; Monika Budnik; Janusz Kochanowski; Miłosz Jaguszewski; Łukasz Szarpak; Tomasz Mazurek; Agnieszka Kapłon-Cieślicka; Grzegorz Opolski; Krzysztof Filipiak. 2021. "Plasma Concentrations of Extracellular Vesicles are Decreased in Patients with Post-Infarct Cardiac Remodelling." Biology 10, no. 2: 97.

Journal article
Published: 05 November 2020 in Journal of Clinical Medicine
Reads 0
Downloads 0

Background: Current guidelines do not suggest in which groups of patients with atrial fibrillation (AF) individual non-vitamin K antagonist oral anticoagulants (NOACs) should be used for the prevention of thromboembolic complications. The aim of this study was to evaluate the frequency of use of apixaban, dabigatran, and rivaroxaban, and attempt to identify factors predisposing their administration. Methods: The Polish Atrial Fibrillation (POL-AF) registry is a prospective, non-interventional study, including consecutive patients with AF hospitalized in ten Polish cardiology centers during the period ranging from January to December 2019. In this study, all patients were treated with NOACs. Results: Among the 2971 patients included in the analysis, 40.4% were treated with rivaroxaban, 32% with apixaban, and 27.6% with dabigatran. The mean age of the total population was 72 ± 11.5 years and 43% were female. A reduced dose of NOAC was used in 35% of patients treated with apixaban, 39.7% of patients treated with dabigatran, and 34.4% of patients treated with rivaroxaban. Independent predictors of apixaban prescription were previous bleeding (OR 2.39, CI 1.69–3.38), GFR < 60 mL/min (OR 1.52, CI 1.28–1.81), and age (per 5 years) (OR 1.13, CI 1.08–1.18), whereas for rivaroxaban the predictor was non-permanent AF (OR 1.24, CI 1.03–1.49) and for dabigatran it was vascular disease (OR 1.22, CI 1.02–1.46). Conclusions: In hospitalized patients with AF, the most frequently chosen NOAC was rivaroxaban. Apixaban was chosen more often in patients after bleeding, and in those who were advanced in years, with heart failure and impaired renal function. Impaired renal function and female gender were factors that diminished the chance of using dabigatran. Previous bleeding and vascular disease was the factor that diminished the chance of using rivaroxaban. Dabigatran and rivaroxaban have been used less frequently in elderly patients.

ACS Style

Iwona Gorczyca; Olga Jelonek; Beata Uziębło-Życzkowska; Magdalena Chrapek; Małgorzata Maciorowska; Maciej Wójcik; Robert Błaszczyk; Agnieszka Kapłon-Cieślicka; Monika Gawałko; Monika Budnik; Tomasz Tokarek; Renata Rajtar-Salwa; Jacek Bil; Michał Wojewódzki; Anna Szpotowicz; Janusz Bednarski; Elwira Bakuła-Ostalska; Anna Tomaszuk-Kazberuk; Anna Szyszkowska; Marcin Wełnicki; Artur Mamcarz; Beata Wożakowska-Kapłon. Trends in the Prescription of Non-Vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation: Results of the Polish Atrial Fibrillation (POL-AF) Registry. Journal of Clinical Medicine 2020, 9, 3565 .

AMA Style

Iwona Gorczyca, Olga Jelonek, Beata Uziębło-Życzkowska, Magdalena Chrapek, Małgorzata Maciorowska, Maciej Wójcik, Robert Błaszczyk, Agnieszka Kapłon-Cieślicka, Monika Gawałko, Monika Budnik, Tomasz Tokarek, Renata Rajtar-Salwa, Jacek Bil, Michał Wojewódzki, Anna Szpotowicz, Janusz Bednarski, Elwira Bakuła-Ostalska, Anna Tomaszuk-Kazberuk, Anna Szyszkowska, Marcin Wełnicki, Artur Mamcarz, Beata Wożakowska-Kapłon. Trends in the Prescription of Non-Vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation: Results of the Polish Atrial Fibrillation (POL-AF) Registry. Journal of Clinical Medicine. 2020; 9 (11):3565.

Chicago/Turabian Style

Iwona Gorczyca; Olga Jelonek; Beata Uziębło-Życzkowska; Magdalena Chrapek; Małgorzata Maciorowska; Maciej Wójcik; Robert Błaszczyk; Agnieszka Kapłon-Cieślicka; Monika Gawałko; Monika Budnik; Tomasz Tokarek; Renata Rajtar-Salwa; Jacek Bil; Michał Wojewódzki; Anna Szpotowicz; Janusz Bednarski; Elwira Bakuła-Ostalska; Anna Tomaszuk-Kazberuk; Anna Szyszkowska; Marcin Wełnicki; Artur Mamcarz; Beata Wożakowska-Kapłon. 2020. "Trends in the Prescription of Non-Vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation: Results of the Polish Atrial Fibrillation (POL-AF) Registry." Journal of Clinical Medicine 9, no. 11: 3565.

Correspondence
Published: 05 October 2020 in Heart
Reads 0
Downloads 0
ACS Style

Agnieszka Kapłon-Cieślicka; Lars H Lund. Atrial fibrillation in heart failure with preserved ejection fraction: a risk marker, risk factor or confounder? Heart 2020, 106, 1949 -1949.

AMA Style

Agnieszka Kapłon-Cieślicka, Lars H Lund. Atrial fibrillation in heart failure with preserved ejection fraction: a risk marker, risk factor or confounder? Heart. 2020; 106 (24):1949-1949.

Chicago/Turabian Style

Agnieszka Kapłon-Cieślicka; Lars H Lund. 2020. "Atrial fibrillation in heart failure with preserved ejection fraction: a risk marker, risk factor or confounder?" Heart 106, no. 24: 1949-1949.

Review
Published: 17 September 2020 in Molecular Neurobiology
Reads 0
Downloads 0

Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family of growth factors that plays a crucial role in the development of the nervous system while supporting the survival of existing neurons and instigating neurogenesis. Altered levels of BDNF, both in the circulation and in the central nervous system (CNS), have been reported to be involved in the pathogenesis of neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), Huntington’s disease (HD), multiple sclerosis (MS), and ischemic stroke. MicroRNAs (miRNAs) are a class of non-coding RNAs found in body fluids such as peripheral blood and cerebrospinal fluid. Several different miRNAs, and their target genes, are recognized to be involved in the pathophysiology of neurodegenerative and neurovascular diseases. Thus, they present as promising biomarkers and a novel treatment approach for CNS disorders. Currently, limited studies provide viable evidence of miRNA-mediated post-transcriptional regulation of BDNF. The aim of this review is to provide a comprehensive assessment of the current knowledge regarding the potential diagnostic and prognostic values of miRNAs affecting BDNF expression and its role as a CNS disorders and neurovascular disease biomarker. Moreover, a novel therapeutic approach in neurodegenerative diseases and ischemic stroke targeting miRNAs associated with BDNF will be discussed.

ACS Style

Ceren Eyileten; Lucia Sharif; Zofia Wicik; Daniel Jakubik; Joanna Jarosz-Popek; Aleksandra Soplinska; Marek Postula; Anna Czlonkowska; Agnieszka Kaplon-Cieslicka; Dagmara Mirowska-Guzel. The Relation of the Brain-Derived Neurotrophic Factor with MicroRNAs in Neurodegenerative Diseases and Ischemic Stroke. Molecular Neurobiology 2020, 58, 329 -347.

AMA Style

Ceren Eyileten, Lucia Sharif, Zofia Wicik, Daniel Jakubik, Joanna Jarosz-Popek, Aleksandra Soplinska, Marek Postula, Anna Czlonkowska, Agnieszka Kaplon-Cieslicka, Dagmara Mirowska-Guzel. The Relation of the Brain-Derived Neurotrophic Factor with MicroRNAs in Neurodegenerative Diseases and Ischemic Stroke. Molecular Neurobiology. 2020; 58 (1):329-347.

Chicago/Turabian Style

Ceren Eyileten; Lucia Sharif; Zofia Wicik; Daniel Jakubik; Joanna Jarosz-Popek; Aleksandra Soplinska; Marek Postula; Anna Czlonkowska; Agnieszka Kaplon-Cieslicka; Dagmara Mirowska-Guzel. 2020. "The Relation of the Brain-Derived Neurotrophic Factor with MicroRNAs in Neurodegenerative Diseases and Ischemic Stroke." Molecular Neurobiology 58, no. 1: 329-347.

Review article
Published: 01 September 2020 in IJC Heart & Vasculature
Reads 0
Downloads 0

Coronavirus disease 2019 (COVID-19) is a novel, highly transmittable and severe strain disease, which has rapidly spread worldwide. Despite epidemiological evidence linking COVID-19 with cardiovascular diseases, little is known about whether and how COVID-19 influences atrial fibrillation (AF), the most prevalent arrhythmia in clinical practice. Here, we review the available evidence for prevalence and incidence of AF in patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and discuss disease management approaches and potential treatment options for COVID-19 infected AF patients.

ACS Style

Monika Gawałko; Agnieszka Kapłon-Cieślicka; Mathias Hohl; Dobromir Dobrev; Dominik Linz. COVID-19 associated atrial fibrillation: Incidence, putative mechanisms and potential clinical implications. IJC Heart & Vasculature 2020, 30, 100631 -100631.

AMA Style

Monika Gawałko, Agnieszka Kapłon-Cieślicka, Mathias Hohl, Dobromir Dobrev, Dominik Linz. COVID-19 associated atrial fibrillation: Incidence, putative mechanisms and potential clinical implications. IJC Heart & Vasculature. 2020; 30 ():100631-100631.

Chicago/Turabian Style

Monika Gawałko; Agnieszka Kapłon-Cieślicka; Mathias Hohl; Dobromir Dobrev; Dominik Linz. 2020. "COVID-19 associated atrial fibrillation: Incidence, putative mechanisms and potential clinical implications." IJC Heart & Vasculature 30, no. : 100631-100631.

Original research article
Published: 02 July 2020 in ESC Heart Failure
Reads 0
Downloads 0

Aims In hospitalized patients with a clinical diagnosis of acute heart failure (HF) with preserved ejection fraction (HFpEF), the aims of this study were (i) to assess the proportion meeting the 2016 European Society of Cardiology (ESC) HFpEF criteria and (ii) to compare patients with restrictive/pseudonormal mitral inflow pattern (MIP) vs. patients with MIP other than restrictive/pseudonormal. Methods and results We included hospitalized participants of the ESC‐Heart Failure Association (HFA) EURObservational Research Programme (EORP) HF Long‐Term Registry who had echocardiogram with ejection fraction (EF) ≥ 50% during index hospitalization. As no data on e', E/e' and left ventricular (LV) mass index were gathered in the registry, the 2016 ESC HFpEF definition was modified as follows: elevated B‐type natriuretic peptide (BNP) (≥100 pg/mL for acute HF) and/or N‐terminal pro‐BNP (≥300 pg/mL) and at least one of the echocardiographic criteria: (i) presence of LV hypertrophy (yes/no), (ii) left atrial volume index (LAVI) of >34 mL/m2), or (iii) restrictive/pseudonormal MIP. Next, all patients were divided into four groups: (i) patients with restrictive/pseudonormal MIP on echocardiography [i.e. with presumably elevated left atrial (LA) pressure], (ii) patients with MIP other than restrictive/pseudonormal (i.e. with presumably normal LA pressure), (iii) atrial fibrillation (AF) group, and (iv) ‘grey area’ (no consistent description of MIP despite no report of AF). Of 6365 hospitalized patients, 1848 (29%) had EF ≥ 50%. Natriuretic peptides were assessed in 28%, LV hypertrophy in 92%, LAVI in 13%, and MIP in 67%. The 2016 ESC HFpEF criteria could be assessed in 27% of the 1848 patients and, if assessed, were met in 52%. Of the 1848 patients, 19% had restrictive/pseudonormal MIP, 43% had MIP other than restrictive/pseudonormal, 18% had AF and 20% were grey area. There were no differences in long‐term all‐cause or cardiovascular mortality, or all‐cause hospitalizations or HF rehospitalizations between the four groups. Despite fewer non‐cardiac comorbidities reported at baseline, patients with MIP other than restrictive/pseudonormal (i.e. with presumably normal LA pressure) had more non‐cardiovascular (14.0 vs. 6.7 per 100 patient‐years, P < 0.001) and cardiovascular non‐HF (13.2 vs. 8.0 per 100 patient‐years, P = 0.016) hospitalizations in long‐term follow‐up than patients with restrictive/pseudonormal MIP. Conclusions Acute HFpEF diagnosis could be assessed (based on the 2016 ESC criteria) in only a quarter of patients and confirmed in half of these. When assessed, only one in three patients had restrictive/pseudonormal MIP suggestive of elevated LA pressure. Patients with MIP other than restrictive/pseudonormal (suggestive of normal LA pressure) could have been misdiagnosed with acute HFpEF or had echocardiography performed after normalization of LA pressure. They were more often hospitalized for non‐HF reasons during follow‐up. Symptoms suggestive of acute HFpEF may in some patients represent non‐HF comorbidities.

ACS Style

Agnieszka Kapłon‐Cieślicka; Cécile Laroche; Maria Generosa Crespo-Leiro; Andrew J.S. Coats; Stefan D. Anker; Gerasimos Filippatos; Aldo Pietro Maggioni; Camilla Hage; Antonio Lara‐Padrón; Alessandro Fucili; Jarosław Drożdż; Petar Seferovic; Giuseppe M.C. Rosano; Alexandre Mebazaa; Theresa McDonagh; Mitja Lainscak; Frank Ruschitzka; Lars H. Lund; Heart Failure Association (HFA) of the European Society of Cardiology (ESC) and the ESC Heart Failure Long‐Term Registry Investigators. Is heart failure misdiagnosed in hospitalized patients with preserved ejection fraction? From the European Society of Cardiology ‐ Heart Failure Association EURObservational Research Programme Heart Failure Long‐Term Registry. ESC Heart Failure 2020, 7, 2098 -2112.

AMA Style

Agnieszka Kapłon‐Cieślicka, Cécile Laroche, Maria Generosa Crespo-Leiro, Andrew J.S. Coats, Stefan D. Anker, Gerasimos Filippatos, Aldo Pietro Maggioni, Camilla Hage, Antonio Lara‐Padrón, Alessandro Fucili, Jarosław Drożdż, Petar Seferovic, Giuseppe M.C. Rosano, Alexandre Mebazaa, Theresa McDonagh, Mitja Lainscak, Frank Ruschitzka, Lars H. Lund, Heart Failure Association (HFA) of the European Society of Cardiology (ESC) and the ESC Heart Failure Long‐Term Registry Investigators. Is heart failure misdiagnosed in hospitalized patients with preserved ejection fraction? From the European Society of Cardiology ‐ Heart Failure Association EURObservational Research Programme Heart Failure Long‐Term Registry. ESC Heart Failure. 2020; 7 (5):2098-2112.

Chicago/Turabian Style

Agnieszka Kapłon‐Cieślicka; Cécile Laroche; Maria Generosa Crespo-Leiro; Andrew J.S. Coats; Stefan D. Anker; Gerasimos Filippatos; Aldo Pietro Maggioni; Camilla Hage; Antonio Lara‐Padrón; Alessandro Fucili; Jarosław Drożdż; Petar Seferovic; Giuseppe M.C. Rosano; Alexandre Mebazaa; Theresa McDonagh; Mitja Lainscak; Frank Ruschitzka; Lars H. Lund; Heart Failure Association (HFA) of the European Society of Cardiology (ESC) and the ESC Heart Failure Long‐Term Registry Investigators. 2020. "Is heart failure misdiagnosed in hospitalized patients with preserved ejection fraction? From the European Society of Cardiology ‐ Heart Failure Association EURObservational Research Programme Heart Failure Long‐Term Registry." ESC Heart Failure 7, no. 5: 2098-2112.

Research article
Published: 27 April 2020 in Cardiovascular Therapeutics
Reads 0
Downloads 0

Introduction. Atrial fibrillation (AF) is associated with high risk of ischemic stroke. The most frequent thrombus location in AF is the left atrial appendage (LAA). Transthoracic echocardiography (TTE) is a basic diagnostic examination in patients (pts) with AF. Objectives. To analyse the relations between basic echocardiographic features, well-established stroke risk factors, type of AF, and anticoagulation therapy with the incidence of left atrial appendage thrombus (LAAT). Patients and Methods. The study group consisted of 768 pts with AF (mean age, 63 years), admitted to three high-reference cardiology departments. Five hundred and twenty-three pts were treated with non-vitamin K antagonist oral anticoagulants (NOACs) and 227 (30%) with vitamin K antagonists (VKAs). The subjects underwent TTE and transesophageal echocardiography (TEE) before cardioversion or ablation. Results. LAAT was significantly more frequent in pts with reduced left ventricular ejection fraction (LVEF): in 10.6% (7 pts) with LVEF<40% and in 9.0% (9 pts) with LVEF 40-49%, while only in 5.5% (33 pts) with LVEF>50%. Compared to pts without LAAT, those with LAAT presented with lower LVEF and higher left atrial diameter (LAD). Multivariate logistic regression revealed the following variables as independent predictors of LAAT: previous bleeding, treatment with VKA, and LVEF. Conclusion. LAAT is related to lower LVEF and higher LAD. LVEF is one of the independent predictors of LAAT. Even in the case of adequate anticoagulant therapy, it might be prudent to consider TEE before cardioversion or ablation in patients with low LVEF and LA enlargement, especially in the coexistence of other thromboembolic risk factors.

ACS Style

Beata Uziębło-Życzkowska; Paweł Krzesiński; Agnieszka Jurek; Agnieszka Kapłon-Cieślicka; Iwona Gorczyca; Monika Budnik; Grzegorz Gielerak; Marek Kiliszek; Monika Gawałko; Piotr Scisło; Janusz Kochanowski; Olga Jelonek; Anna Michalska; Katarzyna Starzyk; Krzysztof J. Filipiak; Beata Wożakowska-Kapłon; Grzegorz Opolski. Left Ventricular Ejection Fraction Is Associated with the Risk of Thrombus in the Left Atrial Appendage in Patients with Atrial Fibrillation. Cardiovascular Therapeutics 2020, 2020, 1 -7.

AMA Style

Beata Uziębło-Życzkowska, Paweł Krzesiński, Agnieszka Jurek, Agnieszka Kapłon-Cieślicka, Iwona Gorczyca, Monika Budnik, Grzegorz Gielerak, Marek Kiliszek, Monika Gawałko, Piotr Scisło, Janusz Kochanowski, Olga Jelonek, Anna Michalska, Katarzyna Starzyk, Krzysztof J. Filipiak, Beata Wożakowska-Kapłon, Grzegorz Opolski. Left Ventricular Ejection Fraction Is Associated with the Risk of Thrombus in the Left Atrial Appendage in Patients with Atrial Fibrillation. Cardiovascular Therapeutics. 2020; 2020 ():1-7.

Chicago/Turabian Style

Beata Uziębło-Życzkowska; Paweł Krzesiński; Agnieszka Jurek; Agnieszka Kapłon-Cieślicka; Iwona Gorczyca; Monika Budnik; Grzegorz Gielerak; Marek Kiliszek; Monika Gawałko; Piotr Scisło; Janusz Kochanowski; Olga Jelonek; Anna Michalska; Katarzyna Starzyk; Krzysztof J. Filipiak; Beata Wożakowska-Kapłon; Grzegorz Opolski. 2020. "Left Ventricular Ejection Fraction Is Associated with the Risk of Thrombus in the Left Atrial Appendage in Patients with Atrial Fibrillation." Cardiovascular Therapeutics 2020, no. : 1-7.

Journal article
Published: 27 February 2020 in Cardiology Journal
Reads 0
Downloads 0

Background: Currently, there is no information on whether in-hospital heart rate (HR) reduction has an influence on risk of death or rehospitalization. The study evaluates the relation between in-hospital HR reduction in heart failure (HF) patients on mortality and rehospitalization within one-year observation. Methods: The analysis included hospitalized Polish patients with sinus rhythm from the European Society of Cardiology Heart Failure Pilot (ESC-HF-Pilot) and ESC Heart Failure Long-Term Registries (ESC-HF-LT), who were divided into two groups: reduced HR and not-reduced HR. HR reduction was defined as a reduced value of HR at discharge compared to admission HR. The primary endpoint (PE) was one-year all-cause death, the secondary endpoint (SE) was one-year all-cause death or rehospitalization for worsening HF. Results: The final analysis included 747 patients; 491 reduced HR (65.7%) and 256 not-reduced HR (34.3%). The PE occurred in 58/476 (12.2%) from reduced HR group and in 26/246 (10.5%) from not-reduced HR group (p = 0.54). In the reduced HR group, independent predictors of PE were age, New York Heart Association (NYHA) class at admission, serum sodium level at admission and systolic blood pressure at discharge. In the not-reduced HR group the independent predictor of PE was diastolic blood pressure at discharge. The SE was observed in 180 patients, 124/398 (31.2%) from reduced HR and 56/207 (27.1%) from the not-reduced HR group (p = 0.30). In the not-reduced HR group only angiotensin converting-enzyme inhibitor usage at discharge was independently associated with lower risk of the SE. Conclusions: In-hospital HR reduction did not influence on the outcomes of HF patients in sinus rhythm.

ACS Style

Paweł Balsam; Michał Peller; Sonia Borodzicz; Agnieszka Kapłon-Cieślicka; Krzysztof Ozierański; Agata Tymińska; Michał Marchel; Maria Generosa Crespo-Leiro; Aldo Pietro Maggioni; Jarosław Drożdż; Marcin Grabowski; Krzysztof J. Filipiak; Grzegorz Opolski. In-hospital heart rate reduction and its relation to outcomes of heart failure patients with sinus rhythm: Results from the Polish part of the European Society of Cardiology Heart Failure Pilot and Long-Term Registries. Cardiology Journal 2020, 27, 25 -37.

AMA Style

Paweł Balsam, Michał Peller, Sonia Borodzicz, Agnieszka Kapłon-Cieślicka, Krzysztof Ozierański, Agata Tymińska, Michał Marchel, Maria Generosa Crespo-Leiro, Aldo Pietro Maggioni, Jarosław Drożdż, Marcin Grabowski, Krzysztof J. Filipiak, Grzegorz Opolski. In-hospital heart rate reduction and its relation to outcomes of heart failure patients with sinus rhythm: Results from the Polish part of the European Society of Cardiology Heart Failure Pilot and Long-Term Registries. Cardiology Journal. 2020; 27 (1):25-37.

Chicago/Turabian Style

Paweł Balsam; Michał Peller; Sonia Borodzicz; Agnieszka Kapłon-Cieślicka; Krzysztof Ozierański; Agata Tymińska; Michał Marchel; Maria Generosa Crespo-Leiro; Aldo Pietro Maggioni; Jarosław Drożdż; Marcin Grabowski; Krzysztof J. Filipiak; Grzegorz Opolski. 2020. "In-hospital heart rate reduction and its relation to outcomes of heart failure patients with sinus rhythm: Results from the Polish part of the European Society of Cardiology Heart Failure Pilot and Long-Term Registries." Cardiology Journal 27, no. 1: 25-37.

Journal article
Published: 22 November 2019 in Kardiologia Polska
Reads 0
Downloads 0
ACS Style

Agnieszka Kapłon-Cieślicka; Monika Budnik; Monika Gawałko; Maciej Wójcik; Robert Błaszczyk; Beata Uziębło-Życzkowska; Paweł Krzesiński; Katarzyna Starzyk; Iwona Gorczyca; Anna Szymańska; Mirosław Dłużniewski; Ludmila Danilowicz-Szymanowicz; Damian Kaufmann; Magdalena Mizia-Szubryt; Maciej Tomasz Wybraniec; Maciej Haberka; Michał Kucio; Anna Tomaszuk-Kazberuk; Katarzyna Wilk; Paweł Burchardt; Kinga Goscinska-Bis; Jarosław Hiczkiewicz; Katarzyna Łojewska; Marek Koziński; Błażej Michalski; Andrzej Tomaszewski; Piotr Scisło; Janusz Kochanowski; Krzysztof J. Filipiak; Grzegorz Opolski. The rationale and design of the LATTEE registry – the first multicenter project on the Scientific Platform of the “Club 30” of the Polish Cardiac Society. Kardiologia Polska 2019, 77, 1078 -1080.

AMA Style

Agnieszka Kapłon-Cieślicka, Monika Budnik, Monika Gawałko, Maciej Wójcik, Robert Błaszczyk, Beata Uziębło-Życzkowska, Paweł Krzesiński, Katarzyna Starzyk, Iwona Gorczyca, Anna Szymańska, Mirosław Dłużniewski, Ludmila Danilowicz-Szymanowicz, Damian Kaufmann, Magdalena Mizia-Szubryt, Maciej Tomasz Wybraniec, Maciej Haberka, Michał Kucio, Anna Tomaszuk-Kazberuk, Katarzyna Wilk, Paweł Burchardt, Kinga Goscinska-Bis, Jarosław Hiczkiewicz, Katarzyna Łojewska, Marek Koziński, Błażej Michalski, Andrzej Tomaszewski, Piotr Scisło, Janusz Kochanowski, Krzysztof J. Filipiak, Grzegorz Opolski. The rationale and design of the LATTEE registry – the first multicenter project on the Scientific Platform of the “Club 30” of the Polish Cardiac Society. Kardiologia Polska. 2019; 77 (11):1078-1080.

Chicago/Turabian Style

Agnieszka Kapłon-Cieślicka; Monika Budnik; Monika Gawałko; Maciej Wójcik; Robert Błaszczyk; Beata Uziębło-Życzkowska; Paweł Krzesiński; Katarzyna Starzyk; Iwona Gorczyca; Anna Szymańska; Mirosław Dłużniewski; Ludmila Danilowicz-Szymanowicz; Damian Kaufmann; Magdalena Mizia-Szubryt; Maciej Tomasz Wybraniec; Maciej Haberka; Michał Kucio; Anna Tomaszuk-Kazberuk; Katarzyna Wilk; Paweł Burchardt; Kinga Goscinska-Bis; Jarosław Hiczkiewicz; Katarzyna Łojewska; Marek Koziński; Błażej Michalski; Andrzej Tomaszewski; Piotr Scisło; Janusz Kochanowski; Krzysztof J. Filipiak; Grzegorz Opolski. 2019. "The rationale and design of the LATTEE registry – the first multicenter project on the Scientific Platform of the “Club 30” of the Polish Cardiac Society." Kardiologia Polska 77, no. 11: 1078-1080.

Journal article
Published: 23 October 2019 in Polish Archives of Internal Medicine
Reads 0
Downloads 0

Galectin-3 (Gal-3) and soluble ST-2 (sST2) have known prognostic value in already diagnosed heart failure (HF). To investigate the association of Gal-3 and sST2 with prognosis in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (pPCI). The analysis was based on data collected in a prospective observational BIOSTRAT (Biomarkers for Risk Stratification After STEMI; NCT03735719) study. Analysis included 117 patients with first-time STEMI treated with pPCI. Serum for Gal-3 and sST2 was sampled 72-96 hours after STEMI admission. The patients were followed for the primary endpoint (cardiovascular (CV) death or HF hospitalization at one year). Both biomarkers correlated significantly with NT-proBNP; Gal-3 correlated with older age. Data on the primary endpoint were available for 104 patients (89%). At one-year observation, 9 patients (8.7%) reached the primary endpoint. In univariate Cox proportional hazards regression analysis, both Gal-3 and sST2 as continuous variables, as well as their newly-established cut-offs (≥9.57 ng/mL for Gal-3 and ≥45.99 ng/mL for sST2, based on Youden index) were predictors of the primary endpoint, and of HF hospitalizations alone. Gal-3 also predicted CV death. After adjustment for age and NT-proBNP, Gal-3 and sST2 remained predictors of the primary endpoint in multivariate models. In patients with first-time STEMI treated with pPCI, baseline Gal-3 and sST2 predicted the composite of CV death and HF hospitalization at one year. Both biomarkers may play an important role in CV risk stratification after STEMI, although Gal-3 may be considered preferable.

ACS Style

Agata Tyminska; Agnieszka Kapłon-Cieślicka; Krzysztof Ozierański; Monika Budnik; Anna Wancerz; Piotr Sypień; Michał Peller; Jakub Maksym; Paweł Balsam; Grzegorz Opolski; Krzysztof J. Filipiak. Association of galectin-3 and soluble ST2 with in-hospital and one-year outcomes in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Polish Archives of Internal Medicine 2019, 1 .

AMA Style

Agata Tyminska, Agnieszka Kapłon-Cieślicka, Krzysztof Ozierański, Monika Budnik, Anna Wancerz, Piotr Sypień, Michał Peller, Jakub Maksym, Paweł Balsam, Grzegorz Opolski, Krzysztof J. Filipiak. Association of galectin-3 and soluble ST2 with in-hospital and one-year outcomes in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Polish Archives of Internal Medicine. 2019; ():1.

Chicago/Turabian Style

Agata Tyminska; Agnieszka Kapłon-Cieślicka; Krzysztof Ozierański; Monika Budnik; Anna Wancerz; Piotr Sypień; Michał Peller; Jakub Maksym; Paweł Balsam; Grzegorz Opolski; Krzysztof J. Filipiak. 2019. "Association of galectin-3 and soluble ST2 with in-hospital and one-year outcomes in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention." Polish Archives of Internal Medicine , no. : 1.

Journal article
Published: 26 August 2019 in Toxins
Reads 0
Downloads 0

Trimethylamine-N-oxide (TMAO) has been suggested as a marker and mediator of cardiovascular diseases. However, data are contradictory, and the mechanisms are obscure. Strikingly, the role of the TMAO precursor trimethylamine (TMA) has not drawn attention in cardiovascular studies even though toxic effects of TMA were proposed several decades ago. We assessed plasma TMA and TMAO levels in healthy humans (HH) and cardiovascular patients qualified for aortic valve replacement (CP). The cytotoxicity of TMA and TMAO in rat cardiomyocytes was evaluated using an MTT test. The effects of TMA and TMAO on albumin and lactate dehydrogenase (LDH) were assessed using fluorescence correlation spectroscopy. In comparison to HH, CP had a two-fold higher plasma TMA (p < 0.001) and a trend towards higher plasma TMAO (p = 0.07). In CP plasma, TMA was inversely correlated with an estimated glomerular filtration rate (eGFR, p = 0.002). TMA but not TMAO reduced cardiomyocytes viability. Incubation with TMA but not TMAO resulted in the degradation of the protein structure of LDH and albumin. In conclusion, CP show increased plasma TMA, which is inversely correlated with eGFR. TMA but not TMAO exerts negative effects on cardiomyocytes, likely due to its disturbing effect on proteins. Therefore, TMA but not TMAO may be a toxin and a marker of cardiovascular risk.

ACS Style

Kinga Jaworska; Dagmara Hering; Grażyna Mosieniak; Anna Bielak-Zmijewska; Marta Pilz; Michał Konwerski; Aleksandra Gasecka; Agnieszka Kapłon-Cieślicka; Krzysztof Filipiak; Ewa Sikora; Robert Hołyst; Marcin Ufnal. TMA, A Forgotten Uremic Toxin, but Not TMAO, Is Involved in Cardiovascular Pathology. Toxins 2019, 11, 490 .

AMA Style

Kinga Jaworska, Dagmara Hering, Grażyna Mosieniak, Anna Bielak-Zmijewska, Marta Pilz, Michał Konwerski, Aleksandra Gasecka, Agnieszka Kapłon-Cieślicka, Krzysztof Filipiak, Ewa Sikora, Robert Hołyst, Marcin Ufnal. TMA, A Forgotten Uremic Toxin, but Not TMAO, Is Involved in Cardiovascular Pathology. Toxins. 2019; 11 (9):490.

Chicago/Turabian Style

Kinga Jaworska; Dagmara Hering; Grażyna Mosieniak; Anna Bielak-Zmijewska; Marta Pilz; Michał Konwerski; Aleksandra Gasecka; Agnieszka Kapłon-Cieślicka; Krzysztof Filipiak; Ewa Sikora; Robert Hołyst; Marcin Ufnal. 2019. "TMA, A Forgotten Uremic Toxin, but Not TMAO, Is Involved in Cardiovascular Pathology." Toxins 11, no. 9: 490.

Observational study
Published: 06 May 2019 in Advances in Clinical and Experimental Medicine
Reads 0
Downloads 0

Pharmacotherapy remains the fundamental method of treating heart failure (HF). Treatment of the elderly is less based on the principles of evidence-based medicine (EBM) and doses do not reach the prescribed value. The aim of the study was to identify any distinct treatment of HF in the elderly compared to those under 65 years of age. This study describes the Polish part of the EURObservational Research Programme: The Heart Failure Pilot Survey (ESC-HF Pilot). Eligibility to the program was limited to people with HF in 26 centers in Poland. After the first phase, more data was collected at 3 and 12 months. It covered a total of 893 people. Treatment of HF is conducted largely in accordance with the applicable guidelines. The percentage of people over 65 years of age who use angiotensin-converting-enzyme inhibitors/angiotensin-II receptor blockers (ACE-I/ARB), β-blockers and mineralocorticoid-antagonists remains high. Also, during the 12-month follow-up the frequency of the use of β-blockers did not decrease, and a decrease in the number subjects treated with ACE-I was compensated by increasing percentage of the use of ARB. A major problem also seems to be the appropriate treatment to prevent thromboembolic complications in the case of coexistence of atrial fibrillation (AF). There is a large group of older people who do not receive proper anticoagulation. The study showed the existence of differences in the treatment of HF in the elderly. It partly does not proceed in accordance with the guidelines, especially in the presence of multiple comorbidities.

ACS Style

Adam Rafał Poliwczak; Janusz Śmigielski; Agnieszka Bała; Ewa Straburzyńska-Migaj; Agata Tyminska; Pawel Balsam; Krzysztof Ozierański; Agnieszka Kapłon-Cieślicka; Joanna Zaprutko; Jarosław Drożdż. Treatment of heart failure in the elderly in Poland. The results of the Polish part of EURObservational Research Programme: The Heart Failure Pilot Survey. Advances in Clinical and Experimental Medicine 2019, 28, 1351 -1358.

AMA Style

Adam Rafał Poliwczak, Janusz Śmigielski, Agnieszka Bała, Ewa Straburzyńska-Migaj, Agata Tyminska, Pawel Balsam, Krzysztof Ozierański, Agnieszka Kapłon-Cieślicka, Joanna Zaprutko, Jarosław Drożdż. Treatment of heart failure in the elderly in Poland. The results of the Polish part of EURObservational Research Programme: The Heart Failure Pilot Survey. Advances in Clinical and Experimental Medicine. 2019; 28 (10):1351-1358.

Chicago/Turabian Style

Adam Rafał Poliwczak; Janusz Śmigielski; Agnieszka Bała; Ewa Straburzyńska-Migaj; Agata Tyminska; Pawel Balsam; Krzysztof Ozierański; Agnieszka Kapłon-Cieślicka; Joanna Zaprutko; Jarosław Drożdż. 2019. "Treatment of heart failure in the elderly in Poland. The results of the Polish part of EURObservational Research Programme: The Heart Failure Pilot Survey." Advances in Clinical and Experimental Medicine 28, no. 10: 1351-1358.

Journal article
Published: 26 April 2019 in Journal of Cardiac Failure
Reads 0
Downloads 0

Heart failure (HF) with preserved ejection fraction (HFpEF) may be misdiagnosed. We assessed prevalence and consistency of Framingham criteria signs and symptoms in acute vs subsequent stable HFpEF. Three hundred ninety-nine patients with acute HFpEF according to Framingham criteria were re-assessed in stable condition. Four definitions of HFpEF at follow-up: (1) Framingham criteria alone, (2) Framingham criteria and natriuretic peptides (NPs), (3) Framingham criteria, NPs, and European Society of Cardiology HF guidelines echocardiographic criteria, (4) Framingham criteria, NPs, and the Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON) trial echocardiographic criteria. At follow-up, HFpEF was still present in 27%, 22%, 21%, and 22%, respectively. Most prevalent in acute HFpEF were dyspnea at exertion (90%), pulmonary rales (71%), persisting at follow-up in 70% and 13%, respectively. Characteristics at acute HF with greater or lesser odds of stable HFpEF; (1) jugular venous distention (odds ratio [OR] 1.80, 95% confidence interval [CI] 1.13-2.87; P = .013) and pleural effusion (OR 0.45, 95% CI 0.24-0.85; P = .014) and (4), older age (1.04, 95% CI 1.01-1.08; P = .014) and tachycardia (>100 bpm) 0.52, 95% CI 0.27-1.00; P = .048). In patients with acute HFpEF, one-quarter met the HF definition according to Framingham criteria at ambulatory follow-up. The proportion of patients with postdischarge HFpEF was largely unaffected by additional echocardiographic or NP criteria Older age and jugular venous distention at acute presentation predicted persistent HFpEF at follow-up, whereas pleural effusion and tachycardia may yield false HFpEF diagnoses. This finding has implications for HFpEF trial design.

ACS Style

Camilla Hage; Ulrika Löfström; Erwan Donal; Emmanuel Oger; Agnieszka Kapłon-Cieślicka; Jean-Claude Daubert; Cecilia Linde; Lars H Lund; Emanuel Oger. Do Patients With Acute Heart Failure and Preserved Ejection Fraction Have Heart Failure at Follow-Up: Implications of the Framingham Criteria. Journal of Cardiac Failure 2019, 26, 1 .

AMA Style

Camilla Hage, Ulrika Löfström, Erwan Donal, Emmanuel Oger, Agnieszka Kapłon-Cieślicka, Jean-Claude Daubert, Cecilia Linde, Lars H Lund, Emanuel Oger. Do Patients With Acute Heart Failure and Preserved Ejection Fraction Have Heart Failure at Follow-Up: Implications of the Framingham Criteria. Journal of Cardiac Failure. 2019; 26 (8):1.

Chicago/Turabian Style

Camilla Hage; Ulrika Löfström; Erwan Donal; Emmanuel Oger; Agnieszka Kapłon-Cieślicka; Jean-Claude Daubert; Cecilia Linde; Lars H Lund; Emanuel Oger. 2019. "Do Patients With Acute Heart Failure and Preserved Ejection Fraction Have Heart Failure at Follow-Up: Implications of the Framingham Criteria." Journal of Cardiac Failure 26, no. 8: 1.

Journal article
Published: 16 January 2019 in Polish Archives of Internal Medicine
Reads 0
Downloads 0

INTRODUCTION The management of heart failure (HF) has changed significantly in recent decades. OBJECTIVES We analyzed the clinical profile, 1‑year outcomes, predictors of mortality, and hospital readmissions in hospitalized patients enrolled in the European Society of Cardiology Heart Failure Pilot Survey (ESC‑HF Pilot) and Heart Failure Long‑Term Registry (ESC‑HF‑LT). PATIENTS AND METHODS The analysis included hospitalized Polish patients from both registries. The primary endpoint was all‑cause death at 1 year, while the secondary endpoint was all‑cause death or hospitalization for worsening HF at 1 year. RESULTS The study included a total of 1415 hospitalized patients (650 from ESC‑HF Pilot; 765 from ESC‑HF‑LT). The primary endpoint occurred in 89 of the 650 patients (13.7%) and in 120 of the 711 patients (16.9%) from ESC‑HF Pilot and ESC‑HF‑LT, respectively (P = 0.11). The secondary endpoint was more frequent in ESC‑HF Pilot than in ESC‑HF‑LT (201 of 509 [39.5%] vs 222 of 663 [33.5%]; P = 0.04). Compared with ESC‑HF Pilot, patients from the ESC‑HF‑LT registry were older and more often had hypertension, atrial fibrillation, peripheral artery disease, and chronic kidney disease, while the incidence of chronic obstructive pulmonary disease was lower. The percentage of patients receiving drugs for HF (diuretics, angiotensin‑converting enzyme inhibitors, angiotensin receptor blockers, β‑blockers, mineralocorticoid receptor antagonists), anticoagulants, cardiac resynchronization therapy, and implantable cardioverter‑defibrillator were higher in the ESC‑HF‑LT group in comparison with the ESC‑HF Pilot group. CONCLUSIONS Patients from the ESC‑HF‑LT registry had a lower risk of death or hospitalization for worsening HF despite the fact that they were older and had more comorbidities. The results might suggest an improvement in physicians' adherence to the guidelines on the management of HF in the ESC‑HF‑LT registry.

ACS Style

Paweł Balsam; Krzysztof Ozierański; Agnieszka Kapłon-Cieślicka; Sonia Borodzicz; Agata Tymińska; Michał Peller; Michał Marchel; Maria Generosa Crespo-Leiro; Aldo Pietro Maggioni; Jarosław Drożdż; Grzegorz Opolski; Marcin Grabowski. Differences in clinical characteristics and 1-year outcomes of hospitalized patients with heart failure in ESC-HF Pilot and ESC-HF-LT registries. Polish Archives of Internal Medicine 2019, 129, 106 -116.

AMA Style

Paweł Balsam, Krzysztof Ozierański, Agnieszka Kapłon-Cieślicka, Sonia Borodzicz, Agata Tymińska, Michał Peller, Michał Marchel, Maria Generosa Crespo-Leiro, Aldo Pietro Maggioni, Jarosław Drożdż, Grzegorz Opolski, Marcin Grabowski. Differences in clinical characteristics and 1-year outcomes of hospitalized patients with heart failure in ESC-HF Pilot and ESC-HF-LT registries. Polish Archives of Internal Medicine. 2019; 129 (2):106-116.

Chicago/Turabian Style

Paweł Balsam; Krzysztof Ozierański; Agnieszka Kapłon-Cieślicka; Sonia Borodzicz; Agata Tymińska; Michał Peller; Michał Marchel; Maria Generosa Crespo-Leiro; Aldo Pietro Maggioni; Jarosław Drożdż; Grzegorz Opolski; Marcin Grabowski. 2019. "Differences in clinical characteristics and 1-year outcomes of hospitalized patients with heart failure in ESC-HF Pilot and ESC-HF-LT registries." Polish Archives of Internal Medicine 129, no. 2: 106-116.

Original article
Published: 16 January 2019 in Cardiovascular Drugs and Therapy
Reads 0
Downloads 0

Current clinical recommendations do not emphasise superiority of any of diuretics, but available reports are very encouraging and suggest beneficial effects of torasemide. This study aimed to compare the effect of torasemide and furosemide on long-term outcomes and New York Heart Association (NYHA) class change in patients with chronic heart failure (HF). Of 2019 patients enrolled in Polish parts of the heart failure registries of the European Society of Cardiology (Pilot and Long-Term), 1440 patients treated with a loop diuretic were included in the analysis. The main analysis was performed on matched cohorts of HF patients treated with furosemide and torasemide using propensity score matching. Torasemide was associated with a similar primary endpoint (all-cause death; 9.8% vs. 14.1%; p = 0.13) occurrence and 23.8% risk reduction of the secondary endpoint (a composite of all-cause death or hospitalisation for worsening HF; 26.4% vs. 34.7%; p = 0.04). Treatment with both torasemide and furosemide was associated with the significantly most frequent occurrence of the primary (23.8%) and secondary (59.2%) endpoints. In the matched cohort after 12 months, NYHA class was higher in the furosemide group (p = 0.04), while furosemide use was associated with a higher risk (20.0% vs. 12.9%; p = 0.03) of worsening ≥ 1 NYHA class. Torasemide use impacted positively upon the primary endpoint occurrence, especially in younger patients (aged < 65 years) and with dilated cardiomyopathy. Our findings contribute to the body of research on the optimal diuretic choice. Torasemide may have advantageous influence on NYHA class and long-term outcomes of HF patients, especially younger patients or those with dilated cardiomyopathy, but it needs further investigations in prospective randomised trials.

ACS Style

Krzysztof Ozierański; Paweł Balsam; Agnieszka Kapłon-Cieślicka; Agata Tymińska; Robert Kowalik; Marcin Grabowski; Michał Peller; Anna Wancerz; Michał Marchel; Maria Generosa Crespo-Leiro; Aldo P. Maggioni; Jarosław Drożdż; Krzysztof J. Filipiak; Grzegorz Opolski. Comparative Analysis of Long-Term Outcomes of Torasemide and Furosemide in Heart Failure Patients in Heart Failure Registries of the European Society of Cardiology. Cardiovascular Drugs and Therapy 2019, 33, 77 -86.

AMA Style

Krzysztof Ozierański, Paweł Balsam, Agnieszka Kapłon-Cieślicka, Agata Tymińska, Robert Kowalik, Marcin Grabowski, Michał Peller, Anna Wancerz, Michał Marchel, Maria Generosa Crespo-Leiro, Aldo P. Maggioni, Jarosław Drożdż, Krzysztof J. Filipiak, Grzegorz Opolski. Comparative Analysis of Long-Term Outcomes of Torasemide and Furosemide in Heart Failure Patients in Heart Failure Registries of the European Society of Cardiology. Cardiovascular Drugs and Therapy. 2019; 33 (1):77-86.

Chicago/Turabian Style

Krzysztof Ozierański; Paweł Balsam; Agnieszka Kapłon-Cieślicka; Agata Tymińska; Robert Kowalik; Marcin Grabowski; Michał Peller; Anna Wancerz; Michał Marchel; Maria Generosa Crespo-Leiro; Aldo P. Maggioni; Jarosław Drożdż; Krzysztof J. Filipiak; Grzegorz Opolski. 2019. "Comparative Analysis of Long-Term Outcomes of Torasemide and Furosemide in Heart Failure Patients in Heart Failure Registries of the European Society of Cardiology." Cardiovascular Drugs and Therapy 33, no. 1: 77-86.

Randomized controlled trial
Published: 26 December 2018 in Platelets
Reads 0
Downloads 0

Activated platelets contribute to thrombosis and inflammation by the release of extracellular vesicles (EVs) exposing P-selectin, phosphatidylserine (PS) and fibrinogen. P2Y12 receptor antagonists are routinely administered to inhibit platelet activation in patients after acute myocardial infarction (AMI), being a combined antithrombotic and anti-inflammatory therapy. The more potent P2Y12 antagonist ticagrelor improves cardiovascular outcome in patients after AMI compared to the less potent clopidogrel, suggesting that greater inhibition of platelet aggregation is associated with better prognosis. The effect of ticagrelor and clopidogrel on the release of EVs from platelets and other P2Y12-exposing cells is unknown. This study compares the effects of ticagrelor and clopidogrel on (1) the concentrations of EVs from activated platelets (primary end point), (2) the concentrations of EVs exposing fibrinogen, exposing PS, from leukocytes and from endothelial cells (secondary end points) and (3) the procoagulant activity of plasma EVs (tertiary end points) in 60 consecutive AMI patients. After the percutaneous coronary intervention, patients will be randomized to antiplatelet therapy with ticagrelor (study group) or clopidogrel (control group). Blood will be collected from patients at randomization, 48 hours after randomization and 6 months following the index hospitalization. In addition, 30 age- and gender-matched healthy volunteers will be enrolled in the study to investigate the physiological concentrations and procoagulant activity of EVs using recently standardized protocols and EV-dedicated flow cytometry. Concentrations of EVs will be determined by flow cytometry. Procoagulant activity of EVs will be determined by fibrin generation test. The compliance and response to antiplatelet therapy will be assessed by impedance aggregometry. We expect that plasma from patients treated with ticagrelor (1) contains lower concentrations of EVs from activated platelets, exposing fibrinogen, exposing PS, from leukocytes and from endothelial cells and (2) has lower procoagulant activity, when compared to patients treated with clopidogrel. Antiplatelet therapy effect on EVs may identify a new mechanism of action of ticagrelor, as well as create a basis for future studies to investigate whether lower EV concentrations are associated with improved clinical outcomes in patients treated with P2Y12 antagonists.

ACS Style

Aleksandra Gasecka; Rienk Nieuwland; Monika Budnik; Françoise Dignat-George; Ceren Eyileten; Paul Harrison; Zenon Huczek; Agnieszka Kapłon-Cieślicka; Romaric Lacroix; Grzegorz Opolski; Kinga Pluta; Edwin Van Der Pol; Marek Postuła; Aurelie Leroyer; Pia Siljander; Auguste Sturk; Krzysztof J. Filipiak. Randomized controlled trial protocol to investigate the antiplatelet therapy effect on extracellular vesicles (AFFECT EV) in acute myocardial infarction. Platelets 2018, 31, 26 -32.

AMA Style

Aleksandra Gasecka, Rienk Nieuwland, Monika Budnik, Françoise Dignat-George, Ceren Eyileten, Paul Harrison, Zenon Huczek, Agnieszka Kapłon-Cieślicka, Romaric Lacroix, Grzegorz Opolski, Kinga Pluta, Edwin Van Der Pol, Marek Postuła, Aurelie Leroyer, Pia Siljander, Auguste Sturk, Krzysztof J. Filipiak. Randomized controlled trial protocol to investigate the antiplatelet therapy effect on extracellular vesicles (AFFECT EV) in acute myocardial infarction. Platelets. 2018; 31 (1):26-32.

Chicago/Turabian Style

Aleksandra Gasecka; Rienk Nieuwland; Monika Budnik; Françoise Dignat-George; Ceren Eyileten; Paul Harrison; Zenon Huczek; Agnieszka Kapłon-Cieślicka; Romaric Lacroix; Grzegorz Opolski; Kinga Pluta; Edwin Van Der Pol; Marek Postuła; Aurelie Leroyer; Pia Siljander; Auguste Sturk; Krzysztof J. Filipiak. 2018. "Randomized controlled trial protocol to investigate the antiplatelet therapy effect on extracellular vesicles (AFFECT EV) in acute myocardial infarction." Platelets 31, no. 1: 26-32.